Emergent BioSolutions (NYSE:EBS) Lowered to Hold Rating by StockNews.com

StockNews.com downgraded shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a report released on Wednesday morning.

Several other research firms have also commented on EBS. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th. Benchmark increased their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Price Performance

EBS opened at $8.88 on Wednesday. The stock’s 50-day moving average price is $8.69 and its 200 day moving average price is $8.17. Emergent BioSolutions has a 12-month low of $1.42 and a 12-month high of $15.10. The firm has a market cap of $481.15 million, a price-to-earnings ratio of -2.17 and a beta of 1.57. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EBS. BNP Paribas Financial Markets lifted its stake in Emergent BioSolutions by 155.3% during the first quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company’s stock worth $414,000 after purchasing an additional 99,520 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Emergent BioSolutions by 14.7% in the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after buying an additional 436,911 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Emergent BioSolutions by 22.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 4,409 shares in the last quarter. Tidal Investments LLC purchased a new position in shares of Emergent BioSolutions in the 1st quarter valued at $34,000. Finally, Cetera Advisors LLC acquired a new stake in Emergent BioSolutions during the 1st quarter worth $428,000. 78.40% of the stock is owned by institutional investors and hedge funds.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.